SCYNEXIS Secures $24.8M from GSK, Advances Lead Antifungal Program SCY-247, and Extends Nasdaq Compliance

summarizeSummary

SCYNEXIS received a significant $24.8 million payment from GSK, improving its liquidity and enabling continued development of its lead antifungal candidate, SCY-247, which showed positive Phase 1 results and is advancing to Phase 2.

check_boxKey Events

• Secured $24.8 Million from GSK

  SCYNEXIS received a one-time, non-refundable payment of $24.8 million from GSK in November 2025, following the termination of the Phase 3 MARIO study for ibrexafungerp. This payment significantly enhances the company's cash position.

• Improved Financial Outlook and Liquidity

  The company reported a reduced net loss of $8.6 million in 2025, a substantial improvement from $21.3 million in 2024. With $56.3 million in cash, cash equivalents, and investments, SCYNEXIS projects sufficient capital to fund operations for at least 12 months.

• Positive Clinical Progress for SCY-247

  The oral formulation of SCY-247 completed Phase 1 studies with positive safety, tolerability, and pharmacokinetic results. An intravenous formulation Phase 1 study was initiated in Q1 2026, with a Phase 2 proof-of-concept study planned for 2026 in Invasive Candidiasis.

• Regulatory Designations for SCY-247

  SCY-247 has been granted Qualified Infectious Disease Product (QIDP) status and Fast Track designations by the FDA, which could provide regulatory exclusivity and expedite the review process if approved.

auto_awesomeAnalysis

SCYNEXIS has significantly bolstered its financial position and advanced its key pipeline asset. The $24.8 million payment from GSK, following the termination of the MARIO study, provides critical liquidity and a projected 12-month operating runway. This cash infusion is substantial for a company of this size. Concurrently, positive Phase 1 results for SCY-247, along with its progression to an intravenous formulation study and a planned Phase 2 trial, underscore the potential of its lead antifungal program. The company also successfully navigated a Nasdaq delisting threat by securing an extension, with a reverse stock split as a potential future measure. The dismissal of prior legal actions further removes a significant overhang. Investors should monitor the progress of SCY-247's clinical trials and GSK's relaunch of BREXAFEMME for continued positive momentum.